Antibody-conjugated liposomes (e.g., trastuzumab-decorated liposomes for HER2-positive cancers) have demonstrated enhanced selective uptake and antitumor efficacy in preclinical and early clinical studies [120]. This evidence concerns the gene ERBB2 and cancer.